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Summary
 
Two major receptors involved in human natural cytotoxicity, NKp46 and NKp44, have re-
cently been identified. However, experimental evidence suggested the existence of additional
such receptor(s). In this study, by the generation of monoclonal antibodies (mAbs), we identi-
fied NKp30, a novel 30-kD triggering receptor selectively expressed by all resting and activated
human natural killer (NK) cells. Although mAb-mediated cross-linking of NKp30 induces strong
NK cell activation, mAb-mediated masking inhibits the NK cytotoxicity against normal or tumor
target cells. NKp30 cooperates with NKp46 and/or NKp44 in the induction of NK-mediated
cytotoxicity against the majority of target cells, whereas it represents the major triggering receptor
in the killing of certain tumors. This novel receptor is associated with CD3
 
z
 
 chains that become
tyrosine phosphorylated upon sodium pervanadate treatment of NK cells. Molecular cloning of
NKp30 cDNA revealed a member of the immunoglobulin superfamily, characterized by a sin-
gle V-type domain and a charged residue in the transmembrane portion. Moreover, we show
that NKp30 is encoded by the previously identified 1C7 gene, for which the function and the
cellular distribution of the putative product were not identified in previous studies.
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N
 
atural killer (NK) cells provide an efficient effector
mechanism by which immunosurveillance eliminates
tumor or virally infected cells (1–3). A well-defined charac-
teristic of NK cells is their ability to lyse target cells defi-
cient in expression of MHC class I molecules (4). This ob-
servation has been the basis for identification of different
inhibitory receptors expressed by NK cells. Upon binding
to MHC class I molecules expressed on target cells, these
receptors deliver inhibitory signals that down-regulate cy-
tolytic functions (1–3, 5, 6). In humans, recognition of
HLA class I molecules is mediated by two types of recep-
tors: those belonging to the Ig superfamily (Ig-SF),
 
1
 
 which
includes both killer inhibitory receptor (KIR; 7–14) and
LIR-1/ILT-2 proteins (15, 16) whose ligands are repre-
sented by various groups of HLA-A, -B, and -C alleles; and
the lectin-like CD94/NKG2A receptor complex (17),
which recognizes HLA-E molecules (18, 19). The expres-
sion of these inhibitory receptors explains how NK cells
can distinguish between HLA-deficient and normal cells
(20, 21). However, limited information existed on the acti-
vating NK receptors responsible for triggering natural cy-
totoxicity. Only recently, two distinct NK-specific recep-
tors have been identified that play an important role in the
NK cell–mediated recognition and killing of HLA class
I–defective target cells. These receptors, termed NKp46
and NKp44 (22, 23), are members of the Ig-SF (24, 25).
Their cross-linking, induced by specific mAbs, leads to a
strong NK cell activation resulting in increased intracellular
Ca
 
2
 
1
 
 levels, triggering of cytotoxicity, and lymphokine re-
lease (22, 23). Importantly, mAb-mediated masking of
NKp46 and/or NKp44 resulted in inhibition of NK cyto-
toxicity against most, but not all, target cells. These find-
ings, while providing evidence for a central role of NKp46
and NKp44 in natural cytotoxicity, also implied the exist-
ence of additional receptors (23, 24, 26).
 
1
 
Abbreviations used in this paper:
 
 GAM, goat anti–mouse antiserum;
HRPO, horseradish peroxidase; Ig-SF, Ig superfamily; ITAM, immu-
noreceptor tyrosine-based activating motif; KIR, killer inhibitory recep-
tor; NCR, natural cytotoxicity receptor; ORF, open reading frame; RT,
reverse transcriptase. 
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In this study, we identified and characterized NKp30, a
third triggering receptor involved in NK cell–mediated
recognition and killing of target cells. NKp30 is a member
of the Ig-SF characterized by a single V-type domain that is
selectively expressed on the surface of human NK cells.
 
Materials and Methods
 
mAbs.
 
The following mAbs were produced in our lab: JT3A
(IgG2a, anti-CD3); BAB281 (22) and KL247 (IgG1 and IgM, re-
spectively, anti-NKp46); Z231 (23) and KS38 (IgG1 and IgM,
respectively, anti-NKp44); KD1 and c127 (IgG2a and IgG1, re-
spectively, anti-CD16); c218 and GPR165 (IgG1 and IgG2a, re-
spectively, anti-CD56); A6-136 (IgM, anti-HLA class I [6]);
GL183 (IgG1, anti-p58.2 [7]); EB6 (IgG1, anti-p58.1 [8]); and
Z199 (IgG2b, anti-NKG2A [17]).
D1.12 (IgG2a, anti–HLA-DR) mAb was provided by Dr. R.S.
Accolla (University of Insubria, Varese, Italy). HP2.6 (IgG2a,
anti-CD4) mAb was provided by Dr. P. Sanchez-Madrid (Hopi-
tal de la Princessa, Madrid, Spain).
The novel mAbs were derived by immunizing 5 wk–old Balb/C
mice with activated (CD3
 
2
 
, CD56
 
1
 
, and CD16
 
1
 
) NK cells,
either NK clones (EC1 and SA260 for A76 and Z25 mAbs, re-
spectively) or a polyclonal NK cell population (for AZ20 mAb).
After different cell fusions, the mAbs were selected for the ability
to induce lysis in redirected killing assays against the Fc
 
g
 
R
 
1
 
 P815
target cells.
 
Purification of PBLs and Generation of Polyclonal or Clonal NK
Cell Populations.
 
PBLs were derived from healthy donors by Fi-
coll-Hypaque gradients and depletion of plastic-adherent cells.
To obtain enriched NK cells, PBLs were incubated with anti-
CD3 (JT3A), anti-CD4 (HP2.6), and anti–HLA-DR (D1.12)
mAbs (30 min at 4
 
8
 
C), followed by goat anti–mouse-coated
Dynabeads (Dynal; 30 min at 4
 
8
 
C) and immunomagnetic deple-
tion (21–23). CD3
 
2
 
4
 
2
 
DR
 
2
 
 cells were used in cytolytic assays or
cultured on irradiated feeder cells in the presence of 100 U/ml
rIL-2 (Proleukin; Chiron Corporation) and 1.5 ng/ml PHA
(GIBCO BRL) to obtain polyclonal NK cell populations or, after
limiting dilution (27), NK cell clones.
 
Flow Cytofluorimetric Analysis.
 
Cells were stained with the ap-
propriate mAb followed by PE- or FITC-conjugated isotype-
specific goat anti–mouse second reagent (Southern Biotechnology
Associates Inc.). Samples were analyzed by one- or two-color
cytofluorimetric analysis (FACScan™; Becton Dickinson), as de-
scribed previously (7).
 
Cell Lines and Cytolytic Assays.
 
The following Fc
 
g
 
R-nega-
tive targets were used: MEL15 (MEL15392, human melanoma
[21]); M14 (human melanoma [24]); SMMC (human hepatocar-
cinoma [26]); A549 (human lung adenocarcinoma, no. CCL-185.1;
American Type Culture Collection). FO-1 and 1174 mel (human
melanomas) were provided by Dr. S. Ferrone (Roswell Park
Cancer Center, Buffalo, NY); AUMA (human melanoma) was
provided by Dr. P. Coulie (Catholic University of Louvain, Brus-
sels, Belgium). The Fc
 
g
 
R-positive target used was P815 (murine
mastocytoma). PHA blasts, used as normal target cells, were ob-
tained by culturing PBLs with 1.5 ng/ml PHA (GIBCO BRL).
Cells were tested for cytolytic activity in a 4-h 
 
51
 
Cr-release as-
say as described previously (8, 26), either in the absence or pres-
ence of various mAbs. The concentrations of the various mAbs
were 10 
 
m
 
g/ml for the masking experiments and 0.5 
 
m
 
g/ml for
the redirected killing experiments. The E/T ratios are indicated
in the text.
 
Determination of Intracellular Free Calcium [Ca
 
2
 
1
 
]
 
i
 
 Increase.
 
De-
termination of [Ca
 
2
 
1
 
]
 
i
 
 was performed as described previously
(28). Fura-2–labeled NK cells were incubated for 30 min at 4
 
8
 
C
with saturating amounts of anti-NKp30 mAb (AZ20) or medium
alone. Cross-linking of this receptor was obtained by adding into
the cuvette 20 
 
m
 
g/ml of affinity-purified goat anti–mouse antise-
rum (GAM; ICN Biomedicals, Inc.).
 
Biochemical Characterization of the NKp30 Molecules.
 
Integral NK
cell membrane proteins (29) were prepared as follows: 25 
 
3
 
 10
 
6
 
cells were lysed in 100 
 
m
 
l TX buffer (20 mM sodium phosphate
buffer, 1% Triton X-114, 10 mM EDTA, pH 8) for 30 min at
4
 
8
 
C, and centrifuged (5 min, 10,000 rpm). The supernatant was
left for 10 min at 37
 
8
 
C, centrifuged, and the lower phase was re-
suspended 1:2 in TX buffer and left for 10 min at 4
 
8
 
C in order to
clarify the lysates. The suspension was then left for 10 min at
37
 
8
 
C, centrifuged, and the lower phase was resuspended 1:3 in
EB (0.0625 M Tris, pH 6.8, 10% glycerol, 2.3% SDS). Samples
were analyzed in discontinuous SDS-PAGE, transferred to Immo-
bilon P (Millipore Corp.), and probed with AZ20 mAb followed
by rabbit anti–mouse horseradish peroxidase (HRPO; DAKO), or
NKp30-specific antiserum followed by donkey anti–rabbit HRPO
(Nycomed Amersham plc). The Renaissance Chemiluminescence
kit (NEN Life Science Products) was used for detection.
 
NKp30 Polyclonal Antiserum.
 
A 2.5-kg HY/Cr male rabbit
(Charles River Laboratories) was immunized with 100 
 
m
 
g/100
 
m
 
l of the 15 amino acid peptide WVSQPPEIRTLEGSC (Euro-
gentec) conjugated with KLH (13). Four weekly treatments were
performed, the first in association with 100 
 
m
 
l CFA and all others
with 100 
 
m
 
l IFA. 1 wk after the last treatment, 10 ml of blood
was drawn, and serum was tested and titered by ELISA against
the immunizing and irrelevant peptides.
 
Analysis of the NKp30 Signal Transduction Complex.
 
NK cells (10
 
8
 
)
were stimulated or not with 100 
 
m
 
M sodium pervanadate (25),
and 1% digitonin lysates were precleared five times with sepharose
protein A–coupled KD1 (anti-CD16) mAb. Lysates were then im-
munoprecipitated with sepharose-CNBr–coupled Z231 and BAB281
mAbs, or with sepharose protein A–coupled NKp30-specific rabbit
antiserum and preimmune rabbit serum. Samples were analyzed in
a 15% SDS-PAGE under reducing conditions (5% 2-ME), trans-
ferred to Immobilon P (Millipore Corp.), and probed with an-
tiphosphotyrosine mAb (PY20-HRPO; Transduction Labora-
tories) or anti-CD3
 
z
 
 mAb (2H2; Immunotech), followed by rabbit
anti–mouse HRPO (DAKO). The Renaissance Chemilumines-
cence kit (NEN Life Science Products) was used for detection.
 
Library Screening by cDNA Expression in COS-7 Cells.
 
The ex-
pression cDNA library was prepared in VR1012 plasmid (Vical
Inc.) using RNA extracted from IL-2–activated polyclonal NK cells
obtained from two healthy donors as described previously (24, 25).
The library screening procedure was as described (24, 25, 30).
In brief, cDNA library was transiently transfected in COS-7 cells,
and selection of positive pools was performed by immunocy-
tochemical staining using the specific anti-NKp30 mAb A76 and
sib-selection.
 
DNA Sequencing.
 
DNA sequencing was performed using
d-Rhodamine Terminator Cycle Sequencing kit and a 377 ABI
Automatic Sequencer (Applied Biosystems/Perkin-Elmer).
 
Transient Transfections.
 
COS-7 cells (5 
 
3
 
 10
 
5
 
/plate) were
transfected with VR1012-NK-A1 (clone 5C) or with the vector
alone by the DEAE-dextran or electroporation methods as de-
scribed (13). After 48 h, transfected cells were used for cytofluori-
metric analysis.
 
Analysis of NKp30 Transcript Expression by Northern Blotting.
 
To analyze NKp30 transcript expression in different cell lines of 
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hemopoietic origin, RNA was size fractionated by denaturing
agarose gel electrophoresis and transferred onto a positively
charged nylon membrane (NEN Life Science Products). In par-
ticular, 10 
 
m
 
g of total RNA prepared using CsCl gradient, or 2 
 
m
 
g
of poly A
 
1
 
 RNA prepared using oligo(dT) magnetic bead separa-
tion (Dynal AS), was loaded on each lane. Northern blots were
performed under high stringency conditions as described (31).
The NKp30 421-bp cDNA probe was obtained by PCR amplifi-
cation performed with 25 pmol of each primer for 30 cycles (30 s
at 94
 
8
 
C, 30 s at 60
 
8
 
C, 30 s at 72
 
8
 
C), followed by a 7-min incuba-
tion at 72
 
8
 
C. The sequences of the primers are: CAG GGC ATC
TCG AGT TTC CGA CAT GGC CTG GAT GCT GTT G
(NK-A1 up) and GAC TAG GAT CCG CAT GTG TAC CAG
CCC CTA GCT GAG GAT G (NK-A1 down). The cDNA
fragment was 
 
32
 
P-labeled by random priming (32).
 
Reverse Transcription PCR Amplification of NKp30 cDNA.
 
Total RNA extracted using RNAzol (Cinna/Biotecx) from
polyclonal NK and T cell populations and clones and from differ-
ent hemopoietic cell lines were reverse transcribed using
oligo(dT) priming. Primers used for cDNA amplification of
NKp30 (606 bp) were the following: 5
 
9
 
 CAG GGC ATC TCG
AGT TTC CGA CAT GGC CTG GAT GCT GTT G (NK-A1
up) and 5
 
9
 
 GAT TTA TTG GGG TCT TTT GAA G (A76-38
reverse). Amplification was performed with 25 pmol of each
primer for 30 cycles (30 s at 94
 
8
 
C, 30 s at 60
 
8
 
C, and 30 s at
72
 
8
 
C), followed by a 7-min incubation at 72
 
8
 
C. The amplifica-
tion products were subcloned in pCR2.1 by TOPO-TA Cloning
kit (Invitrogen), and subsequently sequenced.
 
Zoo-Blot Analysis.
 
Analysis of cross-species conservation of
NKp30 gene was performed using a Zoo-Blot (CLONTECH).
The Southern blot contained genomic DNA from humans,
Rhesus monkey, Sprague–Dawley rat, BALB/c mouse, dog,
cow, rabbit, chicken, and 
 
Saccharomyces cerevisiae
 
 yeast. The hy-
bridization probe was the same 421-bp cDNA fragment used to
hybridize the Northern blot. Washes were carried out at low
stringency conditions as described (32).
 
Results
 
Identification of a Novel NK-specific Triggering Surface Mole-
cule.
 
Mice were immunized with CD3
 
2
 
, CD16
 
1
 
,
CD56
 
1
 
 NK cell clones or bulk populations. mAbs from
different fusions were first selected according to their ability
to induce lysis of the Fc
 
g
 
R
 
1
 
 P815 target cells in a redi-
rected killing assay using polyclonal NK cell populations or
clones as effector cells. Three mAbs, A76, AZ20, and Z25
(all of IgG1 isotype), were selected that induced a strong
cytolytic activity (Fig. 1 A) similar to that elicited by other
mAbs specific for known triggering NK receptors, includ-
ing CD16, NKp46, and NKp44 (22, 23, 26). In Fig. 1 B,
the NK cell cytotoxicity induced by graded amounts of
AZ20 mAb is compared with that of isotype–matched anti-
CD16 or anti-CD56 mAbs. The cytolytic response to
AZ20 mAb paralleled that induced by anti-CD16 mAb,
whereas anti-CD56 mAb had no effect. Moreover, as
shown in Fig. 1 C, a sharp [Ca
 
1
 
]
 
i
 
 increase was detected in
the representative clone 3M16 after stimulation with AZ20
mAb. Notably, [Ca
 
2
 
1
 
]
 
i
 
 increments induced by this Ab oc-
curred only in the presence of a goat anti–mouse second
reagent, allowing efficient cross-linking of the activating
receptor.
Analysis of the cell surface distribution of the molecule(s)
recognized by A76, AZ20, and Z25 mAbs, performed by
indirect immunofluorescence and FACS
 
®
 
 analysis, revealed
reactivity with various activated polyclonal or clonal NK
cell populations derived from different donors (see below).
These also included the infrequent CD16
 
2
 
 NK cell clones.
On the contrary, no mAb reactivity was detected with
PHA-induced polyclonal T cell populations or TCR-
 
a
 
/
 
b
 
and -
 
g
 
/
 
d
 
 T cell clones (derived from different donors).
Neither was any reactivity detected with EBV-induced B
cell lines, monocytic and dendritic cell lines, and different
hemopoietic and nonhemopoietic tumor cell lines, includ-
ing HL60, U937, Eo/A3, THP-1, Daudi, Jurkat, IGROV,
and all the various tumor cell lines used as target cells in this
study (data not shown).
We recently showed that polyclonal NK cell populations
from some donors were characterized by a bimodal distri-
bution of fluorescence intensity of NKp46 molecules
(NKp46
 
bright
 
 and NKp46
 
dull
 
), and that NK clones derived
from these individuals expressed a stable NKp46
 
bright
 
 or
Figure 1. Triggering of NK-mediated cytolytic activity induced by three new mAbs. (A) A representative polyclonal NK cell population was analyzed
for cytolytic activity in a redirected killing assay against the FcgR-positive P815 target cell line in the absence or presence of c127 (anti-CD16), BAB281
(anti-NKp46), Z231 (anti-NKp44), AZ20, A76, Z25, and c218 (anti-CD56) mAbs. The E/T ratio used was 1:1. (B) The representative NK clone 3M16
was analyzed in a redirected killing assay against P815 target cells (E/T ratio 1:1) in the presence of graded amounts of AZ20 (j), c127 (anti-CD16; n),
or c218 (anti-CD56; s) mAbs. All the mAbs used are of the IgG1 isotype. (C) Clone 3M16 was analyzed for [Ca21]i mobilization in the presence of
AZ20 mAb, followed by GAM. The negative control is represented by cells treated with GAM alone. 
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NKp46dull phenotype (26). Importantly, the cytolytic activ-
ity of NK cell clones against NK-susceptible target cells
strictly correlated with their NKp46 phenotype (26). We
then analyzed the reactivity of the new mAbs on polyclonal
NK cell populations and NK cell clones derived from indi-
viduals displaying different patterns of NKp46 expression.
As shown in Fig. 2 A, the polyclonal NK cell population
derived from the representative donor AM displayed a ho-
mogeneously bright phenotype when stained by either
AZ20 or anti-NKp46 mAbs. On the contrary, in the poly-
clonal NK cells derived from donor CB, staining with the
same mAbs resulted in a bimodal distribution of fluores-
cence. Notably, in donor CB, the same pattern of fluores-
cence intensity was also detectable in fresh purified NK
cells (Fig. 2 A). Moreover, the analysis of several clones de-
rived from donor CB revealed that NKp46bright clones were
Figure 2. Cytofluorimetric analysis of resting or activated,
polyclonal or clonal, NK cells. (A) Polyclonal NK cell popula-
tions, derived from donors AM and CB, and freshly isolated NK
cells, derived from donor CB, were analyzed by immunofluo-
rescence and FACS® analysis using c218 (anti-CD56), BAB281
(anti-NKp46), or AZ20 mAbs, followed by PE-conjugated goat
anti–mouse IgG1. The control is represented by cells incubated
with the second reagent alone. (B) NK cell clones, derived from
donor CB, were analyzed by immunofluorescence and FACS®
analysis using BAB281 (anti-NKp46) or AZ20 mAbs, followed
by PE-conjugated goat anti–mouse IgG1.1509 Pende et al.
consistently AZ20bright, whereas NKp46dull clones always
displayed an AZ20dull phenotype (Fig. 2 B).
To further define the pattern of reactivity of the new mAbs
in freshly isolated lymphocytes, PBLs derived from different
individuals were assessed by double fluorescence analysis us-
ing informative mAbs. A representative donor is shown in
Fig. 3 A: the surface molecule recognized by AZ20 mAb
was selectively expressed on CD561 cells. Moreover, most
AZ201 cells coexpressed CD16 molecules. However, AZ20
mAb did not stain CD31 T lymphocytes or HLA-DR1 B
lymphocytes. It is of note that the CD561 AZ202 cell popu-
lation detected in this donor also expressed surface CD3
molecules (not shown). Therefore, also in freshly derived
lymphocytes, the reactivity of AZ20 mAb overlaps with that
of anti-NKp46 mAb. A direct comparative analysis of the
surface expression of NKp46 and AZ20 mAb–reactive mole-
cules is shown in Fig. 3 A. The two molecules were clearly
coexpressed by the same cell subset. However, no diagonal
distribution could be detected in cells stained by AZ20 and
anti-NKp46 mAbs, whereas this type of fluorescence distri-
bution occurred when cells were stained simultaneously by
two anti-NKp46 mAbs of different isotype.
Notably, results identical to those described for AZ20
mAb were obtained with A76 and Z25 mAbs. These data
suggested that the molecule recognized by the new mAbs
may be distinct from NKp46. To directly evaluate this pos-
sibility, COS-7 cells transiently transfected with NKp46
cDNA (24) were analyzed for their reactivity with AZ20,
A76, and Z25 mAbs. Cell transfectants, although reacting
with different anti-NKp46 mAbs, were not stained by
AZ20, A76, and Z25 mAbs (data not shown). Taken to-
gether, these data strongly suggest that A76, AZ20, and Z25
mAbs are specific for a novel surface molecule that defines
all mature human NK cells, but is distinct from NKp46.
To analyze the biochemical characteristics of the surface
molecules recognized by AZ20, A76, and Z25 mAbs, NK
populations were surface labeled with 125I or biotin, immu-
noprecipitated with one or another mAb, and analyzed by
SDS-PAGE. Under these conditions, no specific bands
could be detected. Thus, integral membrane proteins were
prepared from NK cells to further analyze a possible reac-
tivity of the various mAbs in Western blot. As shown in
Fig. 3 B, AZ20 mAb specifically reacted with an z30-kD
molecule, thereafter termed NKp30. Under the same con-
ditions, both A76 and Z25 mAbs displayed a poor reactiv-
ity (data not shown).
Cross-linking of NKp30 Induces Cytolytic Activity in Freshly
Derived NK Cells. Since NKp30 molecule, like NKp46,
was expressed on fresh NK cells, we analyzed whether it
could trigger the cytolytic activity of these cells as demon-
strated previously for NKp46. As shown in Fig. 4 A, AZ20,
A76, and Z25 mAbs induced a strong increase of cytolytic
activity against P815 target cells, whereas the isotype–
matched anti-CD56 mAb had no effect. This triggering ef-
fect was comparable to that obtained with anti-NKp46
mAb. Moreover, in these experiments, the use of AZ20
F(ab9)2 fragments did not induce triggering of cytolytic ac-
tivity, indicating that mAb-dependent NKp30 stimulation
requires efficient cross-linking mediated by FcgR on target
cells (data not shown).
Involvement of NKp30 in the Induction of Natural Cytotoxic-
ity against Normal or Tumor Cells. Previous data showed
Figure 3. Pattern of expression of
NKp30 in PBLs and Western blot analy-
sis. (A) Freshly isolated PBLs, derived
from a representative donor, were ana-
lyzed by two-color immunofluorescence
and FACS® analysis with AZ20 mAb in
combination with GPR 165 (IgG2a,
anti-CD56), KD1 (IgG2a, anti-CD16),
JT3A (IgG2a, anti-CD3), D1-12 (IgG2a,
anti–HLA-DR), and KL247 (IgM, anti-NKp46) mAbs, followed by isotype-
specific FITC- or PE-conjugated GAM second reagents. Double immu-
nofluorescence with two anti-NKp46 mAbs of different isotype (KL247, IgM
vs. BAB281, IgG1) is also shown. The contour plots were divided into quad-
rants representing unstained cells (lower left), cells with only red fluorescence
(upper left), cells with red and green fluorescence (upper right), and cells with
only green fluorescence (lower right). (B) Integral membrane proteins derived
from Daudi (Burkitt lymphoma, negative control) and from a polyclonal NK
cell population were analyzed in an 11% SDS-PAGE under nonreducing
conditions and probed with AZ20 mAb. Molecular weight markers (in kD)
are indicated on the left.1510 NKp30, a Novel Triggering Receptor of Human NK Cells
that mAb-mediated masking of NKp46 or NKp44 inhib-
ited the non–MHC-restricted tumor cell lysis by activated
NK cells (23, 24, 26). Moreover, masking of NKp46 also
inhibited the natural cytotoxicity mediated by freshly iso-
lated peripheral blood NK cells (26). We then evaluated
whether masking of NKp30 could affect the cytolytic ac-
tivity mediated by freshly derived NK cells or NK clones
against a panel of FcgR-negative tumor target cells. As
shown in Fig. 4 B, anti-NKp30 mAb, but not the isotype-
matched anti-CD56 mAb, inhibited natural cytotoxicity
mediated by fresh NK cells against the HLA class I–nega-
tive 1174 mel, AUMA, and FO-1 melanoma cell lines. In
addition, a greater inhibitory effect occurred when anti-
NKp30 mAb was used in combination with anti-NKp46
mAb. This suggests that NKp30 and NKp46 may represent
receptors that act synergistically in triggering the natural
cytotoxicity of fresh NK cells.
In view of these data, we further analyzed the effect of
mAb-mediated masking of NKp30 on the tumor cell kill-
ing by activated NK cells. Fig. 5 shows three representative
NK cell clones analyzed in a cytolytic assay against different
tumor targets, including two melanomas (MEL15 and M14),
a hepatocarcinoma (SMMC), and a lung adenocarcinoma
(A549). In previous studies, we showed that the cytolytic
activity against the M14 melanoma was confined to NK
clones displaying the NKp46bright phenotype and could be
inhibited by mAb-mediated masking of NKp46 receptor.
On the other hand, NKp46bright clones also killed MEL15.
However, neither masking of NKp46 nor of NKp44 sig-
nificantly inhibited their cytolytic activity (26). These data
strongly suggested the existence in these clones of addi-
tional triggering receptors responsible for the cytotoxicity
against MEL15 target cells. As illustrated above, NKp30 is
brightly expressed in NKp46bright clones. Therefore, it is
conceivable that it may play a role in the killing of MEL15
target cells. Indeed, as shown in Fig. 5, anti-NKp30 mAb
sharply inhibited the NK-mediated lysis of MEL15 cells
(.50% of inhibition). Anti-NKp46 mAb exerted a minor
effect, whereas an isotype-matched anti-CD56 mAb had
no effect (data not shown). On the contrary, lysis of M14
melanoma was inhibited by anti-NKp46 mAb, whereas
anti-NKp30 mAb had virtually no effect. Thus, while
NKp46 appears as the major receptor involved in lysis of
M14, NKp30 plays a central role in the killing of MEL15.
Figure 4. NKp30 functions as an activating re-
ceptor in fresh NK cells and is involved in their
natural cytotoxicity. (A) Freshly isolated periph-
eral blood NK lymphocytes, derived from a rep-
resentative donor, were analyzed for cytolytic ac-
tivity in a redirected killing assay against the
FcgR-positive P815 target cell line in the ab-
sence or presence of c127 (anti-CD16), BAB281
(anti-NKp46), AZ20, A76, Z25, and c218 (anti-
CD56) mAbs. The E/T ratio used was 20:1. (B)
Freshly isolated peripheral blood NK cells were
analyzed for cytolytic activity against the indicated FcgR-negative/HLA class I–negative melanoma cell lines either in the absence or presence of mAbs
to the indicated molecules. c218 (anti-CD56), AZ20 (anti-NKp30), and BAB281 (anti-NKp46) mAbs were used. The E/T ratio was 20:1.
Figure 5. Involvement of
NKp30 and NKp46 in the tu-
mor cell lysis mediated by NK
cell clones. Three NK cell clones
were analyzed for cytolytic ac-
tivity against MEL15, M14,
SMMC, and A549 FcgR-nega-
tive target cell lines either in the
absence (white bars) or presence
of AZ20 (anti-NKp30; black bars),
BAB281 (anti-NKp46; striped
bars) or both AZ20 and BAB281
(stippled bars) mAbs. The E/T
ratio was 4:1.1511 Pende et al.
Analysis of the same NK clones in cytolytic assays against
other tumor target cells such as SMMC and A549 (Fig. 5)
revealed a balanced contribution of NKp46 and NKp30 to
the induction of cytotoxicity. Indeed, while mAb-medi-
ated masking of NKp46 or NKp30 alone had a moderate
inhibitory effect, the simultaneous masking of the two
molecules resulted in a significant inhibition. These results
indicate that the two receptors may exert an additive effect
in the induction of cytotoxicity against certain target cells.
Cooperation in NK cell triggering was previously demon-
strated for NKp46 and NKp44 (23). Further analysis re-
vealed that NKp30 could exert an additive effect in the
induction of NK-mediated cytotoxicity, not only with
NKp46, but also with NKp44. Fig. 6 A shows the cytolytic
activity of the representative NK clone MIL69 against FO-1
or A549 tumor cells. Target cell lysis was only partially in-
hibited by mAb-mediated masking of NKp30, NKp44, or
NKp46 receptors. However, the combined masking of two
receptors resulted in a higher inhibitory effect, whereas the
simultaneous masking of the three receptors gave the max-
imal inhibition. Isotype-matched anti-CD56 mAb had no
inhibitory effect either when used alone or in combination
with other mAbs (data not shown).
We further analyzed the role of NKp30 alone or in com-
bination with other receptors in cytolytic assay using PHA-
induced T cell blasts as a source of normal target cells. In
these experiments, lysis of autologous cells by NK cell
clones was obtained by mAb-mediated masking of HLA
class I molecules on target cells to disrupt the interaction
with the HLA class I–specific inhibitory receptors ex-
pressed on NK cells. Also under these experimental condi-
tions, the mAb-mediated masking of single receptors had
only a partial inhibitory effect on cytotoxicity (Fig. 6 B).
On the other hand, the simultaneous masking of NKp30,
NKp46, and NKp44 receptors strongly reduced (or virtu-
ally abrogated) target cell lysis (see the representative clones
MX361 and P9). These data support the notion that the
ligands recognized by these receptors are expressed not
only in tumor, but also in normal cells.
Finally, we analyzed the possible involvement of NKp30
in the recognition of murine target cells. Previous studies
indicated that the NK-mediated killing of murine cells was
abrogated by the mAb-mediated masking of NKp46 recep-
tors, thus suggesting that NKp46 may represent the unique
human NK receptor able to recognize ligand(s) expressed
on murine cells (24, 26). This hypothesis was substantiated
by the recent identification of a murine homologue that
shared a high degree of identity with the human NKp46
receptor (33). Although not shown, the mAb-mediated
masking of NKp30 had no effect on the lysis of both
BW1502 and YAC-1 murine thymoma target cells.
Altogether, the above data indicate that NKp30 func-
tions as a major receptor involved in the NK-mediated cy-
totoxicity against normal target cells and most, but not all,
tumor cells. In addition, NKp30 may cooperate with
NKp46 and NKp44, most likely depending on the expres-
sion of specific ligands by the target cell analyzed.
Molecular Cloning of the cDNA Encoding the NKp30 Mole-
cule. In an attempt to identify the cDNA encoding the
NKp30 molecule, a cDNA expression library was gener-
ated from the mRNA of human polyclonal NK cells (24).
COS-7 cells transfected with different cDNA library pools
were stained with A76 mAb by an immunocytochemical
detection method. A 674-bp cDNA (NK-A1 clone 5C; se-
quence data available from EMBL/GenBank/DDBJ under
accession no. AJ223153) was isolated that contained a sin-
Figure 6. NKp30 cooperates
with NKp46 and NKp44 in the
induction of NK-mediated cyto-
toxicity against tumor or normal
autologous target cells. (A) The
representative NK clone MIL69
was analyzed for cytolytic activ-
ity against FO-1 or A549 FcgR-
negative target cell lines either
in the absence or presence of
mAbs to the indicated mole-
cules. The following mAbs were
used: KL247 (anti-NKp46), AZ20
(anti-NKp30), and KS38 (anti-
NKp44). The E/T ratios were 2:1
(FO-1) and 3:1 (A549). (B) Two
NK cell clones (MX361 and P9)
were analyzed for cytolytic activ-
ity against autologous PHA blasts
either in the absence (white bars)
or presence of mAbs to the in-
dicated molecules (black bars). The
mAbs used were A6-136 (anti–
HLA class I [cl I]), KL247 (anti-
NKp46), KS38 (anti-NKp44),
and AZ20 (anti-NKp30). The
E/T ratio was 10:1.1512 NKp30, a Novel Triggering Receptor of Human NK Cells
gle open reading frame (ORF) of 573 bp. Transfection of
COS-7 cells with clone 5C cDNA construct resulted in the
surface expression of a molecule that was recognized by all
the various anti-NKp30 mAbs (Fig. 7 A), but not by anti-
NKp46 mAbs as assessed by cytofluorimetric analysis. As
shown in Fig. 7 B, clone 5C ORF encoded a putative 190
amino acid polypeptide belonging to the Ig-SF, character-
ized by a signal peptide of 18 amino acids and by an extra-
cellular region of 120 amino acids forming an Ig-like do-
main of the V type. The extracellular portion contains two
potential N-linked glycosylation sites and no consensus se-
quences for O-linked glycosylation. A region rich in hy-
drophobic amino acids, potentially involved in protein–
protein interactions, is connecting the Ig V-like domain
with the transmembrane region. The 19 amino acid trans-
membrane region contains the positively charged amino
acid, Arg, and the 33 amino acid cytoplasmic portion lacks
typical immunoreceptor tyrosine-based activating motif
(ITAM) consensus sequences. The presence of a charged
amino acid in the transmembrane domain is a feature com-
mon to other triggering receptors expressed on NK cells
(24, 25, 34–37). These charged residues are usually thought
to be involved in the association with ITAM-containing
signaling polypeptides.
Searching EMBL/GenBank/DDBJ databases revealed
that the clone 5C cDNA was identical to a previously
identified alternatively spliced form of the 1C7 gene (avail-
able under accession no. AF031138). This gene has been
mapped on human chromosome 6, in the TNF cluster of
the MHC gene complex (38). To date, however, owing to
the lack of specific mAb, neither the function nor the sur-
face distribution of the putative product of 1C7 gene could
be identified. Moreover, the 1C7 transcript could not be
revealed by Northern blot on different tissues and cell lines.
On the other hand, by reverse transcriptase (RT)-PCR,
the 1C7 transcript could be amplified by RNA isolated
from spleen (but not from other tissues) or certain lym-
phoid and myeloid cell lines. These data suggested that
1C7 transcripts could be poorly represented, or could be
expressed at substantial levels only in a narrow range of cell
types (39). Our present analysis of NKp30 expression by
Northern blotting revealed a mRNA of z1 kb in poly-
clonal NK cell populations and NK cell lines, including
NKL and NK3.3. On the contrary, consistent with the lack
of reactivity with anti-NKp30 mAbs, no NKp30 mRNA
could be detected in human monocytes or cell lines of dif-
ferent histotype, including U937, Jurkat, HL60, and LCL
721.221 cells (Fig. 8 A). In some of these cell lines that were
negative for mRNA expression by Northern blot (and for
anti-NKp30 mAb surface staining), it has been possible to
detect transcripts when analyzed by the RT-PCR tech-
nique. This finding is likely to reflect a low level of NKp30
transcription resulting in lack of NKp30 surface expression.
Moreover, Northern blot analysis of multiple human tissues
showed selective expression of NKp30 transcript only in
spleen cells (data not shown). Altogether, these data are
consistent with the notion that NKp30 expression is largely
NK specific.
Finally, the human NKp30 cDNA probe hybridized
with genomic DNA from monkey, rat, mouse, dog, cow,
and rabbit. These data suggest that the NKp30-encoding
gene may be conserved in different species (Fig. 8 B).
Biochemical Characterization of the NKp30 Complex. An
NKp30-specific antiserum was generated by immunizing
rabbits with an NH2-terminal NKp30 peptide. As shown in
Fig. 9 A, the antiserum recognized in Western blot a mole-
cule identical to that previously detected by AZ20 mAb.
Unlike the AZ20 mAb, the antiserum immunoprecipitates
NKp30 molecules from polyclonal NK cell populations la-
beled with biotin (data not shown). Thus, a polyclonal NK
cell population, treated or not with sodium pervanadate,
was immunoprecipitated with the NKp30-specific antise-
rum and probed with antiphosphotyrosine mAb. To avoid
nonspecific binding of rabbit Ig to CD16 molecules, cell
lysates were extensively precleared with anti-CD16 mAb.
Moreover, in all experiments, preimmune rabbit serum was
used as negative control. In these experiments, no tyrosine
phosphorylation of NKp30 receptor could be detected
(data not shown). On the other hand, NKp30 receptor as-
sociated with a molecule that became tyrosine phosphory-
lated upon sodium pervanadate treatment (Fig. 9 B) and
comigrated with the NKp46-associated CD3z chain. The
Figure 7. Cytofluorimetric analysis of the NKp30 molecules expressed in COS-7
cell transfectants; amino acid sequence and hydrophobicity plot of NKp30. (A) COS-7
cells transfected with clone 5C cDNA construct were stained with anti-NKp30 (A76,
AZ20, and Z25) or with anti-NKp46 (BAB281) mAbs followed by PE-conjugated
goat anti–mouse IgG1, and analyzed by flow cytometry. White profiles represent cells incubated with the second reagent alone (i.e., negative controls).
(B) The putative signal peptide is indicated in lowercase letters, and the transmembrane region is underlined. Cysteines involved in the Ig-like fold are cir-
cled, and putative N-glycosylation sites are boxed. A Kyte-Doolittle hydrophobicity plot is shown at the bottom. DNA and protein sequence analyses were
performed using GeneWorks, MacVector suites, NetOGlyc version 2.0 (available at http://www.cbs.dtu.dk/services/NetOGlyc), and PSORT Prediction
Servers (available at http://psort.nibb.ac.jp:8800/). The sequence data are available from EMBL/GenBank/DDBJ under accession no. AJ223153.1513 Pende et al.
identity between the NKp30-associated molecule and
CD3z polypeptides was directly demonstrated by its reac-
tivity with anti-CD3z mAb (Fig. 9 B).
Thus, NKp30, similar to other NK triggering receptors
including CD16 (34, 35) and NKp46 (23), can transduce
activating signals via association with the ITAM-containing
CD3z polypeptides. These data are in agreement with the
lack of ITAM in the NKp30 cytoplasmic tail, and with the
presence of a charged residue in its transmembrane portion.
Discussion
In this study, because of the generation of specific mAbs,
we identified and characterized NKp30, a novel triggering
receptor that plays an important role in the natural cytotox-
icity of both resting and activated human NK cells. Similar
to NKp46, NKp30 is selectively expressed by all NK cells,
both freshly isolated and cultured in IL-2, thus representing
an optimal marker for NK cell identification. Although it
belongs to the Ig-SF, NKp30 does not display any substan-
tial homology with previously identified NK receptors.
In many respects, NKp30 appeared similar to NKp46.
Indeed, their parallel expression on all NK cells (including
the rare CD162 cells), the existence for both of a high or
low density pattern of surface expression, together with
their similar functional characteristics, led to the thought
that the surface molecule recognized by the new mAbs
could be identical or strictly related to NKp46. However,
NKp30 and NKp46 displayed different molecular masses
and, functionally, appeared to play a complementary role in
the induction of natural cytotoxicity. Moreover, molecular
cloning revealed that NKp30 is a protein with very limited
homology with NKp46, as the two molecules display only
13% identity and 15% similarity, and are encoded by genes
located on different chromosomes.
The receptors responsible for the NK cell triggering dur-
ing natural cytotoxicity and tumor cell lysis have remained
elusive until recently. Available data were consistent with
the hypothesis of the existence of multiple triggering NK
receptors involved in natural cytotoxicity. In this context,
Figure 8. Northern blot anal-
ysis of NKp30 transcript expres-
sion and Zoo-Blot analysis. (A)
Total RNA was isolated from
cells of different origin. Lanes 1
and 2, polyclonal NK cell popu-
lations; lane 3, blank; lane 4, an
NK cell line (NKL); lane 5, an
NK cell line (NK3.3); lane 6, hu-
man monocytes; lane 7, a histio-
cytic lymphoma cell line (U937);
lane 8, a T lymphoma cell line
(Jurkat); lane 9, an acute promy-
elocytic leukemia cell line (HL60);
and lane 10, an EBV-transformed
B cell line (LCL721.221). 10 mg
of each RNA preparation (2 mg
of poly A1 RNA from poly-
clonal NK cell populations, lanes
1 and 2) were hybridized with
the 421-bp NKp30 cDNA probe.
The positions of 28S and 18S ri-
bosomal RNA subunits are indi-
cated on the left. (B) A Southern blot containing genomic DNA from humans, Rhesus monkey, Sprague-Dawley rat, BALB/c mouse, dog, cow, rabbit,
chicken, and S. cerevisiae yeast was hybridized under low stringency condition with the 421-bp NKp30 cDNA probe.
Figure 9. Biochemical analysis of the NKp30 receptor complex by the
use of a specific antiserum. (A) Integral membrane proteins derived from
Daudi (as negative control) and from a polyclonal NK cell population
were analyzed in an 11% SDS-PAGE under nonreducing conditions and
probed with NKp30-specific rabbit antiserum (I). Molecular weight
markers (in kD) are indicated on the left. (B) 1% digitonin cell lysates de-
rived from a polyclonal NK cell population, untreated (2) or treated (1)
with sodium pervanadate, were immunoprecipitated with Z231 mAb
(anti-NKp44), BAB281 mAb (anti-NKp46), NKp30-specific rabbit anti-
serum (I), and preimmune rabbit serum (pI). Samples were analyzed in a
15% SDS-PAGE under reducing conditions and probed with either an-
tiphosphotyrosine (anti-PTyr) or anti-CD3z (anti-z) mAbs. Ig light
chains (Ig(L)), tyrosine-phosphorylated CD3z (P-z), tyrosine-phosphory-
lated KARAP/DAP12 (P-KARAP/DAP12), and the nonphosphorylated
form of CD3z (z) are indicated by arrows. Molecular weight markers (in
kD) are indicated on the right.1514 NKp30, a Novel Triggering Receptor of Human NK Cells
we recently identified NKp46 and NKp44, two receptors
involved in recognition and lysis of a variety of tumor tar-
gets. Both belong to the Ig-SF, but neither displays signifi-
cant identity. They associate to different signal transducing
polypeptides (CD3z/FceRIg and KARAP/DAP12, re-
spectively) that become tyrosine phosphorylated upon NK
cell activation. NKp46 and NKp44 were shown to cooper-
ate in the process of tumor cell lysis by human NK cells.
However, lysis of certain target cells was only marginally
NKp46 and/or NKp44 dependent, since mAb-mediated
masking of these molecules did not significantly interfere
with cytotoxicity (26). This finding strongly suggested the
existence of additional triggering receptors that could in-
duce cytotoxicity against these target cells. Moreover, al-
though clearly NKp46 and/or NKp44 dependent, the cy-
tolytic activity against other tumor cell lines could not be
abrogated by mAb-mediated masking of both molecules,
suggesting again the existence of additional receptor(s) co-
operating with NKp46 and NKp44. Indeed, we show here
that NKp30 represents a receptor that may cooperate with
NKp46 and NKp44 in the induction of cytotoxicity against
a variety of target cells. Perhaps more importantly, NKp30
represents the major receptor in inducing NK-mediated
killing of certain tumor target cells, the lysis of which is
largely NKp46/NKp44 independent. Remarkably, NKp30,
similar to NKp46, is also involved in NK cell activation
and target cell killing by fresh NK cells.
As discussed above, the surface expression of NKp30
parallels that of NKp46. Indeed, NK cells displaying an
NKp46dull or an NKp46bright phenotype were also charac-
terized by NKp30dull or NKp30bright fluorescence. We
showed previously that NK cell clones characterized by an
NKp46dull phenotype consistently express low amounts of
NKp44 (26). The finding that NK cells express parallel den-
sities of different triggering receptors may explain the exist-
ence of NK cell subsets displaying different “natural” cy-
tolytic activity. For example, it was difficult to understand
why the cytolytic activity against some target cells (such as
MEL15), although largely NKp46 independent, was essen-
tially confined to NK clones expressing the NKp46bright phe-
notype. These results can now be explained by the finding
that only NKp46bright cells express a high density of NKp30
receptor. Thus, the previous demonstration of major differ-
ences in cytolytic activity of NKp46dull and NKp46bright cells
can now be applied also to NK cells displaying different
NKp30 phenotypes. Along this line, the cytolytic activity of
NKp30dull NK cell clones was markedly reduced compared
with NKp30bright clones (data not shown).
NKp30, similar to NKp46, associates with CD3z, which
is most likely involved in signaling via the receptor com-
plex. However, CD3z does not appear to be necessary for
the surface expression of both receptors, at least in COS-7
cells (this report, and reference 24). Molecular cloning re-
vealed that NKp30 is the product of 1C7, a gene previ-
ously mapped on human chromosome 6 in the HLA class
III region (38, 39). However, neither the function nor the
cellular distribution of the putative product of 1C7 gene
was known, and no indications existed of its role in natural
cytotoxicity. In addition, the analysis of 1C7 transcript ex-
pression was limited to RT-PCR, whereas no detection
had been possible by Northern blot analysis (39). It should
also be stressed that no correlation between transcript and
surface expression could be established because of the lack
of specific mAbs. In this study, we show that a precise cor-
relation exists between the surface expression of NKp30, as
determined by staining with three different mAbs, and
mRNA expression, as assessed by Northern blot. On the
contrary, the detection of 1C7 transcripts by RT-PCR
does not allow prediction of the surface expression of the
1C7/NKp30 molecule.
In conclusion, the NKp30 molecule represents a third
member of an emerging family of receptors, termed natural
cytotoxicity receptors (NCRs; [40]), that are involved in
NK cell triggering upon recognition of non-HLA ligands.
These receptors appear to complement each other in the
induction of target cell lysis by NK cells. The relative con-
tribution of each receptor is likely to reflect the expression/
density of their specific ligands on target cells. It has re-
cently been shown that CD16 is also involved in natural
cytotoxicity, thus suggesting that in addition to Fc binding
and antibody-dependent cell-mediated cytotoxicity, CD16
may play a role in the regulation of NK cell function (41).
Besides CD16 and the different NCRs, several other sur-
face molecules that can mediate NK cell triggering have
been identified in humans and rodents. These include CD2
(42, 43), CD69 (44), CD28 (45), 2B4 (46), and NKR-P1
(47). However, their actual role in natural cytotoxicity has
yet to be clarified, since in most instances these activating
structures are not NK restricted.
Finally, although the identification of different NCRs
constitutes a major step forward in our understanding of
the NK cell physiology, both the nature and the distribu-
tion of the NCR ligands on target cells remain to be deter-
mined. Based on the available data, it is possible to envisage
a novel mechanism of tumor escape consisting in the
downregulation (on tumor cells) of ligand molecules spe-
cifically recognized by NK-specific triggering receptors.
Thus, the identification of such ligands will allow the anal-
ysis of their distribution in normal versus tumor cells, and
define whether a correlation exists between ligand expres-
sion and susceptibility to NK-mediated lysis by different
tumor cells.
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